IMA 401
Alternative Names: IMA-401; IMA401 TCER™; MAGE A4/8 TCERLatest Information Update: 20 Sep 2024
At a glance
- Originator immatics biotechnologies GmbH
- Developer Bristol-Myers Squibb; Immatics N.V.
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Sep 2024 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Solid tumours released by Immatics
- 11 May 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater), in Germany (NCT05359445)
- 10 May 2022 Immatics N.V. plans a phase I clinical trial in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in Germany by May 2022 (NCT05359445)